US 2012/0231004 A1 · ANTIBODIES

Abstract

The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to the Ephrin type-A receptor 10 with high affinity. Nucleic acid molecules encoding the Ephrin type-A receptor 10 antibodies, expression vectors, host cells and methods for expressing the Ephrin type-A receptor 10 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Ephrin type-A receptor 10 antibodies are also provided. Methods for detecting the Ephrin type-A receptor 10, as well as methods for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer are disclosed.

Claims10

Dependent claims

An isolated antibody which specifically binds EPHA10 (SEQ ID NO:43) comprising:

a) a heavy chain variable region comprising:
i) a first CDR comprising a sequence at least 80% identical to SEQ ID NO:
56;
ii) a second CDR comprising a sequence at least 84% identical to SEQ ID NO:57;
iii) a third CDR comprising a sequence at least 90% identical to SEQ ID NO:58;
and
b) a light chain variable region comprising:
i) a first CDR comprising a sequence at least 80% identical to SEQ ID NO:
59;
ii) a second CDR comprising a sequence at least 84% identical to SEQ ID NO:60;
iii) a third CDR comprising a sequence at least 90% identical to SEQ ID NO:61.

8 more elements

Dependencies are inferred from the claim text.

Antibodies

Life of this patent

Antibodies

Life of this patent

Abstract

Claims10